Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)

Trial Profile

Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs GEH 120714 (Primary)
  • Indications Inflammation; Multiple sclerosis
  • Focus Adverse reactions; First in man
  • Sponsors GE Healthcare
  • Most Recent Events

    • 23 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 23 Jun 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
    • 23 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top